Non-Hodgkin lymphoma Posts on Medivizor
Navigation Menu

Non-Hodgkin lymphoma Posts on Medivizor

Increased rituximab dose for elderly male patients with diffuse large B-cell lymphoma

Posted by on Oct 20, 2017 in Non-Hodgkin lymphoma | 0 comments

In a nutshell The authors looked at increasing the dose of rituximab for elderly male patients with diffuse large B-cell lymphoma. The authors concluded that the higher dose improved patient outcomes and was just as safe as the lower dose.  Some background Diffuse large B-cell lymphoma (DLBCL) is a type of non-Hodgkin lymphoma. It is...

Read More

Rituximab, bendamustine, and low-dose cytarabine treatment for elderly patients with mantle cell lymphoma

Posted by on Oct 19, 2017 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study looked at the safety and effectiveness of rituximab (Rituxan), bendamustine (Treanda), and low-dose cytarabine (Cytosar) for treating elderly patients with mantle cell lymphoma. The study concluded that this treatment is effective at treating elderly patients with mantle cell lymphoma, but has some adverse events.  Some...

Read More

Effectiveness of idelalisib treatment for patients with relapsed or refractory follicular lymphoma

Posted by on Oct 19, 2017 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study looked at the safety and effectiveness of idelalisib treatment for patients with relapsed or difficult to treat follicular lymphoma. The study concluded that idelalisib can be used safely to treat these patients.  Some background Follicular lymphoma (FL) is an incurable type of non-Hodgkin lymphoma. Patient outcomes...

Read More

Using 18F-FDG PET scans to determine future outcomes for patients with mantle cell lymphoma

Posted by on Oct 14, 2017 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study looked at how well 18F-FDG positron emission tomography (PET) scans can determine future patient outcomes for patients with relapsed or difficult to treat mantle cell lymphoma. The study concluded that 18F-FDG PET scans can determine future patient outcomes, and negative PET scans indicate positive outcomes.  Some...

Read More

Bendamustine plus rituximab to treat patients with indolent B-cell lymphoma or mantle cell lymphoma

Posted by on Oct 14, 2017 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study looked at how effective the combination of bendamustine plus rituximab was at treating patients with indolent B-cell non-Hodgkin lymphoma (B-NHL) and mantle cell lymphoma (MCL). The study concluded that bendamustine plus rituximab is safe and effective for treating patients with indolent B-NHL and MCL.  Some...

Read More

Using obintuzumab plus CHOP or bendamustine to treat patients with follicular lymphoma

Posted by on Oct 14, 2017 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study compared the effectiveness of obinutuzumab (Gazyva) plus CHOP chemotherapy vs obinutuzumab plus bendamustine (Treanda) in treating patients with follicular lymphoma. The study concluded that both obinutuzumab plus CHOP and obinutuzumab plus bendamustine are effective at treating patients with follicular...

Read More

Obinutuzumab vs rituximab treatment for patients with advanced stage follicular lymphoma

Posted by on Oct 13, 2017 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study compared rituximab (Rituxan)-based treatment to obinutuzumab (Gazyva)-based treatment in patients with advanced stage follicular lymphoma. The study concluded that obinutuzumab-based therapy leads to longer progression-free survival.  Some background Follicular lymphoma (FL) is a type of non-Hodgkin lymphoma...

Read More

A review of rituximab maintenance treatment for patients with diffuse large B-cell lymphoma

Posted by on Oct 12, 2017 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study examined the effectiveness of rituximab maintenance treatment for patients with diffuse large B-cell lymphoma (DLBCL). The review concluded that rituximab maintenance treatment increases progression-free survival in patients with DLBCL.  Some background Diffuse large B-cell lymphoma (DLBCL) is a common type of...

Read More

Autologous stem cell transplantation in patients with mantle cell lymphoma

Posted by on Oct 12, 2017 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study compared the effectiveness of autologous stem cell transplantation in patients with mantle cell lymphoma who either did or did not achieve a complete response after first line treatment. The study concluded that autologous stem cell transplantation is most useful for patients who have already achieved a complete...

Read More

The use of rituximab maintenance therapy after autologous stem cell transplantation for patients with mantle cell lymphoma

Posted by on Oct 7, 2017 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study looked at the effect of rituximab maintenance therapy for mantle cell lymphoma patients who have already received an autologous stem cell transplantation. The study concluded that rituximab maintenance therapy greatly improves outcomes for patients with mantle cell lymphoma.  Some background Mantle cell lymphoma (MCL)...

Read More

Comparison between rituximab and CT-P10 biosimilar medication for the treatment of patients with advanced stage follicular lymphoma

Posted by on Oct 7, 2017 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study compared rituximab (Rituxan) and CT-P10 treatments for patients with previously untreated advanced stage follicular lymphoma. The study concluded that CT-P10 is just as safe and effective as name-brand rituximab.  Some background Follicular lymphoma (FL) is a type of non-Hodgkin lymphoma. It is commonly treated...

Read More